HIGHLIGHTS
- who: Tekle Pauzaite and colleagues from the Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster , YQ, UK have published the research work: Dbf4-Cdc7 (DDK) Inhibitor PHA-767491 Displays Potent Anti-Proliferative Effects via Crosstalk with the CDK2-RB-E2F Pathway, in the Journal: Biomedicines 2022, 2012 of /2022/
- what: The authors investigate the requirements of DDK activity in the initiation phase of DNA replication using small_molecule DDK inhibitors PHA-767491 and XL-413. This study provides mechanistic insight into the differential cytotoxic effects seen for XL-413 and PHA-767491 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.